Boston Scientific BSX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $20.08B+19.9% | $16.75B+17.6% | $14.24B+12.3% | $12.68B+6.7% | ||
| $6.22B+18.3% | $5.26B+21.0% | $4.35B+9.9% | $3.96B+6.6% | ||
| $13.85B+20.6% | $11.49B+16.1% | $9.89B+13.4% | $8.73B+6.7% | ||
| 69%+0.4pp | 68.6%-0.9pp | 69.5%+0.7pp | 68.8%0.0pp | ||
| $6.89B+15.1% | $5.98B+15.3% | $5.19B+14.8% | $4.52B+3.7% | ||
| $10.24B+15.2% | $8.89B+17.7% | $7.55B+6.7% | $7.08B+1.4% | ||
| $3.61B+38.8% | $2.6B+11.1% | $2.34B+42.1% | $1.65B+37.5% | ||
| 18%+2.5pp | 15.5%-0.9pp | 16.5%+3.5pp | 13%+2.9pp | ||
| $349M+14.4% | $305M+14.7% | $266M-43.4% | $470M+37.8% | ||
| $3.39B+48.3% | $2.28B+15.0% | $1.99B+73.8% | $1.14B+6.1% | ||
| $492M+12.8% | $436M+10.9% | $393M-11.1% | $442M+1,095% | ||
| $2.89B+56.7% | $1.85B+15.9% | $1.59B+128% | $698M-32.9% | ||
| 14.4%+3.4pp | 11%-0.2pp | 11.2%+5.7pp | 5.5%-3.3pp | ||
| $1.94+55.2% | $1.25+16.8% | $1.07+138% | $0.45-34.8% | ||
| $4.98B+28.6% | $3.87B+9.4% | $3.54B+27.1% | $2.79B+21.5% | ||
| 24.8%+1.7pp | 23.1%-1.7pp | 24.9%+2.9pp | 22%+2.7pp | ||
| $3.61B+38.8% | $2.6B+11.1% | $2.34B+42.1% | $1.65B+37.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Boston Scientific's revenue?
- Boston Scientific (BSX) generated $20.6B in revenue over the trailing twelve months, up 17.4% year over year.
- Is Boston Scientific profitable?
- Boston Scientific reported $3.6B in net income over the trailing twelve months, a 17.3% net margin.
- What are Boston Scientific's profit margins?
- Gross margin is 69.2% and operating margin is 18.4%, with a 17.3% net margin.
- What is Boston Scientific's earnings per share?
- Boston Scientific's diluted EPS over the trailing twelve months is $2.39.
- Where does Boston Scientific's income statement data come from?
- Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
